SCHEMBL2317569

SCHEMBL2317569

CC(C)(NC(=O)Nc1ccc(F)c(C(F)(F)F)c1)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.52
CHRNA7 P36544 1/20 0.45
PLTP P55058 4/20 0.45
BLM P54132 1/20 0.44
WRN Q14191 1/20 0.44
RORC P51449 1/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
IDH2 P48735 2/20 0.42
DGAT1 O75907 1/20 0.41
GRM4 Q14833 1/20 0.41
DHODH Q02127 2/20 0.39
RAF1 P04049 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
FGFR1 P11362 1/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2315078 0.91 DHODH (0.49) ARPLTPBLMRORCMAPT
SCHEMBL2316339 0.87 RORC (0.47) PLTPRORCMAPTLMNADGAT1
SCHEMBL2317084 0.86 MAPT (0.45) PLTPRORCMAPTLMNATP53
SCHEMBL2318318 0.84 FPR2 (0.46) PLTPRORCMAPTDGAT1ALDH1A1
SCHEMBL2490168 0.82 PLTP (0.51) PLTPRORCDGAT1ALDH1A1
SCHEMBL2360023 0.82 TRPV1 (0.49) PLTPRORCMAPTLMNATP53
SCHEMBL2358812 0.80 TRPV1 (0.46) PLTPRORCMAPTLMNATP53
SCHEMBL2491471 0.80 RORC (0.45) PLTPRORCMAPTTP53DGAT1
SCHEMBL2316628 0.79 RORC (0.48) PLTPRORCMAPTDGAT1ALDH1A1
SCHEMBL2312708 0.78 TP53 (0.50) PLTPRORCMAPTTP53DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 AR 1353/4885CHRNA7 4608/4885PLTP 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.